Cardax, Inc. Overview
Industry: Biotechnology
Sector: Healthcare
Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii. Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin Read MoreCardax, Inc. is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.
Cardax, Inc.
Score
Recent News
Earnings Per Share
Score 2.00/5
Cardax, Inc. earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Biotechnology industry
, Halozyme Therapeutics Inc
, Corcept Therapeutics Incorporated
, Exelixis Inc
are companies with high ratings.
Return on Equity
Score 1.69/5
Cardax, Inc. exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
In
Biotechnology industry
, Halozyme Therapeutics Inc
, Corcept Therapeutics Incorporated
, Exelixis Inc
are companies with high ratings.
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
Net Margin
Score 0.81/5
Cardax, Inc.
olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
In
Biotechnology industry
, Halozyme Therapeutics Inc
, Corcept Therapeutics Incorporated
, Exelixis Inc
are companies with high ratings.
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
Leverage
Score 3.00/5
Cardax, Inc.
attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
, also exhibit high scores.
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
In
Biotechnology industry
, Halozyme Therapeutics Inc
, Corcept Therapeutics Incorporated
, Exelixis Inc
are companies with high ratings.
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios
